{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:33:31Z","timestamp":1788140011294,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"crossref","award":["18411967800"],"award-info":[{"award-number":["18411967800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008410","name":"Shanghai Municipal Population and Family Planning Commission","doi-asserted-by":"publisher","award":["201640069"],"award-info":[{"award-number":["201640069"]}],"id":[{"id":"10.13039\/501100008410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["17ZR1405700"],"award-info":[{"award-number":["17ZR1405700"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"crossref","award":["Y-2019Roche-171"],"award-info":[{"award-number":["Y-2019Roche-171"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"crossref","award":["SHDC12018X03"],"award-info":[{"award-number":["SHDC12018X03"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10549-020-05730-2","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T21:02:56Z","timestamp":1591822976000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia"],"prefix":"10.1007","volume":"182","author":[{"given":"Jinfeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-3106","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"issue":"2","key":"5730_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA: A Cancer J Clin 65(2):87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"CA: A Cancer J Clin"},{"issue":"10","key":"5730_CR2","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/1097-0142(19881115)62:10<2226::aid-cncr2820621026>3.0.co;2-d","volume":"62","author":"C Kamby","year":"1988","unstructured":"Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT (1988) Metastatic pattern in recurrent breast cancer special reference to intrathoracic recurrences. Cancer 62(10):2226\u20132233. https:\/\/doi.org\/10.1002\/1097-0142(19881115)62:10<2226:aid-cncr2820621026>3.0.co;2-d","journal-title":"Cancer"},{"key":"5730_CR3","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.2147\/ijn.S58275","volume":"9","author":"S Sun","year":"2014","unstructured":"Sun S, Tang L, Zhang J, Lv F, Wang Z, Wang L, Zhang Q, Zheng C, Qiu L, Jia Z, Lu Y, Liu G, Shao Z, Wang B, Hu X (2014) Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomed 9:1443\u20131452. https:\/\/doi.org\/10.2147\/ijn.S58275","journal-title":"Int J Nanomed"},{"issue":"Suppl 1","key":"5730_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3816\/cbc.2002.s.006","volume":"3","author":"V Heinemann","year":"2002","unstructured":"Heinemann V (2002) Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clinical Breast Cancer 3(Suppl 1):24\u201329. https:\/\/doi.org\/10.3816\/cbc.2002.s.006","journal-title":"Clinical Breast Cancer"},{"issue":"1","key":"5730_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/ijc.28966","volume":"136","author":"J Zhang","year":"2015","unstructured":"Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, Wu J, Shao Z (2015) Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer 136(1):204\u2013211. https:\/\/doi.org\/10.1002\/ijc.28966","journal-title":"Int J Cancer"},{"issue":"1","key":"5730_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","volume":"52","author":"JS Reis-Filho","year":"2008","unstructured":"Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52(1):108\u2013118. https:\/\/doi.org\/10.1111\/j.1365-2559.2007.02889.x","journal-title":"Histopathology"},{"issue":"3","key":"5730_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.breast.2010.02.003","volume":"19","author":"N Koshy","year":"2010","unstructured":"Koshy N, Quispe D, Shi R, Mansour R, Burton GV (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19(3):246\u2013248. https:\/\/doi.org\/10.1016\/j.breast.2010.02.003","journal-title":"Breast"},{"issue":"9","key":"5730_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3978\/j.issn.2072-1439.2014.08.13","volume":"6","author":"Q Jiao","year":"2014","unstructured":"Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J (2014) The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 6(9):1329\u20131335. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2014.08.13","journal-title":"J Thorac Dis"},{"issue":"40","key":"5730_CR9","doi-asserted-by":"publisher","first-page":"43135","DOI":"10.18632\/oncotarget.5654","volume":"6","author":"J Zhang","year":"2015","unstructured":"Zhang J, Fan M, Xie J, Wang Z, Wang B, Zhang S, Wang L, Cao J, Tao Z, Li T, Hu X (2015) Chemotherapy of metastatic triple negative breast cancer: experience of using platinum-based chemotherapy. Oncotarget 6(40):43135\u201343143. https:\/\/doi.org\/10.18632\/oncotarget.5654","journal-title":"Oncotarget"},{"issue":"4","key":"5730_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/s1470-2045(15)70064-1","volume":"16","author":"XC Hu","year":"2015","unstructured":"Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, Yin YM, Wu CP, Jiang ZF, Wang XJ, Lou GY, Liu DG, Feng JF, Luo JF, Sun K, Gu YJ, Wu J, Shao ZM (2015) Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 16(4):436\u2013446. https:\/\/doi.org\/10.1016\/s1470-2045(15)70064-1","journal-title":"Lancet Oncol"},{"issue":"8","key":"5730_CR11","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/annonc\/mdy209","volume":"29","author":"J Zhang","year":"2018","unstructured":"Zhang J, Lin Y, Sun XJ, Wang BY, Wang ZH, Luo JF, Wang LP, Zhang S, Cao J, Tao ZH, Wu J, Shao ZM, Yang WT, Hu XC (2018) Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncology: Off J Eur Soc Med Oncol 29(8):1741\u20131747. https:\/\/doi.org\/10.1093\/annonc\/mdy209","journal-title":"Ann Oncology: Off J Eur Soc Med Oncol"},{"issue":"9","key":"5730_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994\u20131007. https:\/\/doi.org\/10.1038\/sj.ki.5002786","journal-title":"Kidney Int"},{"issue":"2","key":"5730_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0163-7258(87)90009-x","volume":"34","author":"A Eastman","year":"1987","unstructured":"Eastman A (1987) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34(2):155\u2013166. https:\/\/doi.org\/10.1016\/0163-7258(87)90009-x","journal-title":"Pharmacol Ther"},{"issue":"47","key":"5730_CR14","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265\u20137279. https:\/\/doi.org\/10.1038\/sj.onc.1206933","journal-title":"Oncogene"},{"key":"5730_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0079-6603(01)67026-0","volume":"67","author":"SM Cohen","year":"2001","unstructured":"Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93\u2013130. https:\/\/doi.org\/10.1016\/s0079-6603(01)67026-0","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"issue":"20","key":"5730_CR16","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.1158\/0008-5472.Can-09-4521","volume":"70","author":"K Hastak","year":"2010","unstructured":"Hastak K, Alli E, Ford JM (2010) Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Can Res 70(20):7970\u20137980. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-4521","journal-title":"Can Res"},{"issue":"Suppl 2","key":"5730_CR17","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.3816\/CBC.2009.s.006","volume":"9","author":"CG Murphy","year":"2009","unstructured":"Murphy CG, Seidman AD (2009) Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clinical Breast Cancer 9(Suppl 2):S58\u201365. https:\/\/doi.org\/10.3816\/CBC.2009.s.006","journal-title":"Clinical Breast Cancer"},{"issue":"4","key":"5730_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4048\/jbc.2014.17.4.339","volume":"17","author":"JS Kim","year":"2014","unstructured":"Kim JS, Park IH, Lee KS, Ro J (2014) Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients. J Breast Cancer 17(4):339\u2013343. https:\/\/doi.org\/10.4048\/jbc.2014.17.4.339","journal-title":"J Breast Cancer"},{"issue":"6","key":"5730_CR19","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.7314\/apjcp.2013.14.6.3711","volume":"14","author":"C Erten","year":"2013","unstructured":"Erten C, Demir L, Somali I, Alacacioglu A, Kucukzeybek Y, Akyol M, Can A, Dirican A, Bayoglu V, Tarhan MO (2013) Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev: APJCP 14(6):3711\u20133717. https:\/\/doi.org\/10.7314\/apjcp.2013.14.6.3711","journal-title":"Asian Pac J Cancer Prev: APJCP"},{"issue":"17","key":"5730_CR20","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","volume":"44","author":"L Bodnar","year":"2008","unstructured":"Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcislo K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44(17):2608\u20132614. https:\/\/doi.org\/10.1016\/j.ejca.2008.08.005","journal-title":"Eur J Cancer"},{"issue":"2","key":"5730_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ki.2015.115","volume":"88","author":"RL Mehta","year":"2015","unstructured":"Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, Chakaravarthi R, Holden AL, Goldstein SL (2015) Phenotype standardization for drug-induced kidney disease. Kidney Int 88(2):226\u2013234. https:\/\/doi.org\/10.1038\/ki.2015.115","journal-title":"Kidney Int"},{"issue":"2","key":"5730_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5049\/ebp.2014.12.2.55","volume":"12","author":"GS Oh","year":"2014","unstructured":"Oh GS, Kim HJ, Shen A, Lee SB, Khadka D, Pandit A, So HS (2014) Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press 12(2):55\u201365. https:\/\/doi.org\/10.5049\/ebp.2014.12.2.55","journal-title":"Electrolyte Blood Press"},{"issue":"2","key":"5730_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/clpt.1988.132","volume":"44","author":"G Daugaard","year":"1988","unstructured":"Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44(2):164\u2013172. https:\/\/doi.org\/10.1038\/clpt.1988.132","journal-title":"Clin Pharmacol Ther"},{"key":"5730_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/2050-6511-15-70","volume":"15","author":"T Oka","year":"2014","unstructured":"Oka T, Kimura T, Suzumura T, Yoshimoto N, Nakai T, Yamamoto N, Matsuura K, Mitsuoka S, Yoshimura N, Kudoh S, Hirata K (2014) Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study. BMC Pharmacol Toxicol 15:70. https:\/\/doi.org\/10.1186\/2050-6511-15-70","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"5730_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","volume":"25","author":"H Lajer","year":"1999","unstructured":"Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25(1):47\u201358. https:\/\/doi.org\/10.1053\/ctrv.1999.0097","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"5730_CR26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.clon.2006.06.011","volume":"18","author":"E Hodgkinson","year":"2006","unstructured":"Hodgkinson E, Neville-Webbe HL, Coleman RE (2006) Magnesium depletion in patients receiving cisplatin-based chemotherapy. Clinical Oncol 18(9):710\u2013718. https:\/\/doi.org\/10.1016\/j.clon.2006.06.011","journal-title":"Clinical Oncol"},{"issue":"2","key":"5730_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00280-006-0266-x","volume":"59","author":"JH Seo","year":"2007","unstructured":"Seo JH, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS, Kim AR, Lee JB, Koo BH (2007) Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 59(2):269\u2013274. https:\/\/doi.org\/10.1007\/s00280-006-0266-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"5730_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4143\/crt.2008.40.3.101","volume":"40","author":"JH Kim","year":"2008","unstructured":"Kim JH, Oh SY, Kwon HC, Lee S, Kim SH, Kim DC, Lee JH, Lee HS, Cho SH, Kim HJ (2008) Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer. Cancer Res Treat: Off J Korean Cancer Assoc 40(3):101\u2013105. https:\/\/doi.org\/10.4143\/crt.2008.40.3.101","journal-title":"Cancer Res Treat: Off J Korean Cancer Assoc"},{"issue":"1","key":"5730_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12032-010-9793-8","volume":"29","author":"LG Brito","year":"2012","unstructured":"Brito LG, de Andrade JM, Lins-Almeida T, Zola FE, Pinheiro MN, Marana HR, Tiezzi DG, Peria FM (2012) Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients. Med Oncol 29(1):33\u201338. https:\/\/doi.org\/10.1007\/s12032-010-9793-8","journal-title":"Med Oncol"},{"key":"5730_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12885-015-1170-8","volume":"15","author":"Y Chen","year":"2015","unstructured":"Chen Y, Han F, Cao LH, Li C, Wang JW, Li Q, Zheng W, Guo ZX, Li AH, Zhou JH (2015) Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound. BMC Cancer 15:136. https:\/\/doi.org\/10.1186\/s12885-015-1170-8","journal-title":"BMC Cancer"},{"issue":"1","key":"5730_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2006.06.013","volume":"54","author":"JH Kim","year":"2006","unstructured":"Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ, Song HH, Lee KS, Zang DY, Ahn JS, Park YL, Lee JA (2006) A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer 54(1):57\u201362. https:\/\/doi.org\/10.1016\/j.lungcan.2006.06.013","journal-title":"Lung Cancer"},{"issue":"1","key":"5730_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2009.05.018","volume":"68","author":"K Funai","year":"2010","unstructured":"Funai K, Takamochi K, Itaya T, Mochizuki T, Nakamura T, Toyoda F, Yong-Il K, Sasaki K, Momiki S, Takahashi T, Neyatani H, Suzuki K (2010) Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer. Lung Cancer 68(1):78\u201383. https:\/\/doi.org\/10.1016\/j.lungcan.2009.05.018","journal-title":"Lung Cancer"},{"issue":"11","key":"5730_CR33","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2(11):2490\u20132518. https:\/\/doi.org\/10.3390\/toxins2112490","journal-title":"Toxins"},{"issue":"5","key":"5730_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22(5):609\u2013619. https:\/\/doi.org\/10.1634\/theoncologist.2016-0319","journal-title":"Oncologist"},{"key":"5730_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.radonc.2019.01.015","volume":"134","author":"EA Aalbersberg","year":"2019","unstructured":"Aalbersberg EA, Rossi MM, de Wit-van der Veen LJ, Walraven I, van den Heuvel MM, Sonke JJ, Belderbos JS, Vogel WV (2019) Pre-hydration in cisplatin-based CCRT: effects on tumour concentrations and treatment outcome. Radiother Oncol: J Eur Soc Therap Radiol Oncol 134:30\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2019.01.015","journal-title":"Radiother Oncol: J Eur Soc Therap Radiol Oncol"},{"issue":"2","key":"5730_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0167-8140(00)00203-6","volume":"56","author":"B Biedermann","year":"2000","unstructured":"Biedermann B, Landmann C, Kann R, Passweg J, Soler M, Lohri A, Rochlitz C, Herrmann R, Pless M (2000) Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer. Radiother Oncol: J Eur Soc Therap Radiol Oncol 56(2):169\u2013173. https:\/\/doi.org\/10.1016\/s0167-8140(00)00203-6","journal-title":"Radiother Oncol: J Eur Soc Therap Radiol Oncol"},{"issue":"9","key":"5730_CR37","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/jco.1994.12.9.1814","volume":"12","author":"MB Hazuka","year":"1994","unstructured":"Hazuka MB, Crowley JJ, Bunn PA Jr, O'Rourke M, Braun TJ, Livingston RB (1994) Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study. J Clin Oncol: Off J Am Soc Clin Oncol 12(9):1814\u20131820. https:\/\/doi.org\/10.1200\/jco.1994.12.9.1814","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"37","key":"5730_CR38","doi-asserted-by":"publisher","first-page":"6907","DOI":"10.3748\/wjg.v23.i37.6907","volume":"23","author":"S Semb","year":"2017","unstructured":"Semb S, Helgstrand F, Hjorne F, Bytzer P (2017) Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication. World J Gastroenterol 23(37):6907\u20136910. https:\/\/doi.org\/10.3748\/wjg.v23.i37.6907","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5730_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2478\/v10019-008-0010-8","volume":"42","author":"N Besic","year":"2008","unstructured":"Besic N, Zagar S, Pilko G, Peric B, Hocevar MJR (2008) Influence of magnesium sulphate infusion before total thyroidectomy on transient hypocalcemia\u2014a randomised study. Radiol Oncol 42(3):143\u2013150","journal-title":"Radiol Oncol"},{"issue":"3","key":"5730_CR40","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.clcc.2016.02.011","volume":"15","author":"DM Jiang","year":"2016","unstructured":"Jiang DM, Dennis K, Steinmetz A, Clemons M, Asmis TR, Goodwin RA, Vickers MM (2016) Management of epidermal growth factor receptor inhibitor-induced hypomagnesemia: a systematic review. Clin Colorectal Cancer 15(3):e117\u2013123. https:\/\/doi.org\/10.1016\/j.clcc.2016.02.011","journal-title":"Clin Colorectal Cancer"},{"key":"5730_CR41","doi-asserted-by":"crossref","unstructured":"Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N. (2017). Platinum-containing regimens for metastatic breast cancer. Cochrane Database Sys Rev, 6:Cd003374. doi:10.1002\/14651858.CD003374.pub","DOI":"10.1002\/14651858.CD003374.pub4"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-020-05730-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05730-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:46:22Z","timestamp":1623282382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-020-05730-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5730"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05730-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"11 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the FUSCC Ethics Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}